Lack of effect of ustekinumab in treatment of allergic contact dermatitis |
| |
Authors: | Bangsgaard Nannie Zachariae Claus Menné Torkil Skov Lone |
| |
Institution: | Department of Dermato-Allergology, University Hospital of Copenhagen, 2900 Hellerup, Denmark. Nanban01@geh.regionh.dk |
| |
Abstract: | Background. Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL‐12 and IL‐23, shown to be effective and safe for patients with psoriasis. Despite both IL‐12 and IL‐23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported. Objectives. To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis. Methods. A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department. Results. Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect. Conclusion. Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis. |
| |
Keywords: | allergic contact dermatitis treatment ustekinumab |
本文献已被 PubMed 等数据库收录! |
|